IOLCP Recent Expansions.
-
Investment in property, plant and equipment increased during
the year mainly due to installation of new manufacturing
facilities for production of Pantoprazole, capital work in
progress for installation of new manufacturing facilities of
Metformin and purchase of additional land. -
During the year, the Company has successfully set up Unit VI to
manufacture “Pantoprazole” and has started its trial production. The
installed capacity of the “Unit VI” is 240 MT per annum with a capex
of ` 33.83 Crore, which is met through internal accruals only. -
Successful setting up a new Unit VII for manufacturing of ‘Metformin’ with the additional capacity of 7,200 MT per annum with capex of~ 28 Crore which is funded fully through internal accruals. Presently, the Company is operating existing unit for Metformin, having installed capacity of 4,000 MT per annum, which is fully utilized. With this additional capacity, now the total installed capacity of Metformin is 11,200 MT per annum.